CA2896939C - Treatment of hyperhidrosis - Google Patents

Treatment of hyperhidrosis Download PDF

Info

Publication number
CA2896939C
CA2896939C CA2896939A CA2896939A CA2896939C CA 2896939 C CA2896939 C CA 2896939C CA 2896939 A CA2896939 A CA 2896939A CA 2896939 A CA2896939 A CA 2896939A CA 2896939 C CA2896939 C CA 2896939C
Authority
CA
Canada
Prior art keywords
itpr2
use according
nucleic acid
acid molecule
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2896939A
Other languages
English (en)
French (fr)
Other versions
CA2896939A1 (en
Inventor
Niklas Dahl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HIDROS THERAPEUTICS INTERNATIONAL AB
Original Assignee
HIDROS THERAPEUTICS INTERNATIONAL AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HIDROS THERAPEUTICS INTERNATIONAL AB filed Critical HIDROS THERAPEUTICS INTERNATIONAL AB
Publication of CA2896939A1 publication Critical patent/CA2896939A1/en
Application granted granted Critical
Publication of CA2896939C publication Critical patent/CA2896939C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA2896939A 2013-01-03 2013-12-13 Treatment of hyperhidrosis Active CA2896939C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361748592P 2013-01-03 2013-01-03
US61/748,592 2013-01-03
PCT/SE2013/051508 WO2014107124A1 (en) 2013-01-03 2013-12-13 Treatment of hyperhidrosis

Publications (2)

Publication Number Publication Date
CA2896939A1 CA2896939A1 (en) 2014-07-10
CA2896939C true CA2896939C (en) 2022-07-12

Family

ID=51062371

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2896939A Active CA2896939C (en) 2013-01-03 2013-12-13 Treatment of hyperhidrosis

Country Status (6)

Country Link
US (2) US9809820B2 (https=)
EP (1) EP2958572B1 (https=)
JP (1) JP6242402B2 (https=)
CN (1) CN105025903B (https=)
CA (1) CA2896939C (https=)
WO (1) WO2014107124A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9809820B2 (en) * 2013-01-03 2017-11-07 Hidros Therapeutics International Ab Treatment of hyperhidrosis
WO2016150723A1 (en) 2015-03-20 2016-09-29 Unilever Plc Antiperspirant composition
CN110643598A (zh) * 2018-06-26 2020-01-03 煌鼎科技有限公司 促进皮肤凹疤愈合及毛孔收缩的酵母dna原料制法
WO2024104663A1 (en) 2022-11-16 2024-05-23 Unilever Ip Holdings B.V. Method of reducing malodour

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0019055D0 (en) * 2000-08-03 2000-09-27 Unilever Plc Antiperspirant and deodorant products and methods for their use
EP2298315A1 (en) 2002-08-28 2011-03-23 Harbor BioSciences, Inc. Therapeutic treatment methods
ATE443765T1 (de) * 2003-03-21 2009-10-15 Santaris Pharma As Analoga kurzer interferierender rna (sirna)
WO2005116204A1 (ja) * 2004-05-11 2005-12-08 Rnai Co., Ltd. Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法
CN101340884A (zh) 2005-10-19 2009-01-07 曼尼·马纳舍·辛格尔 用于治疗多汗症的方法
ES2671874T3 (es) * 2007-10-18 2018-06-11 Rose U, Llc Formulaciones tópicas de glicopirrolato
CN102300578A (zh) 2008-12-01 2011-12-28 延寿有限责任公司 用于改变健康、安康和寿命的方法和组合物
WO2011020114A2 (en) * 2009-08-14 2011-02-17 Allergan, Inc. Methods of treating cancer using tachykinin retargeted endopeptidases
WO2012112422A1 (en) * 2011-02-14 2012-08-23 Allergan, Inc. Inhibiting aberrant blood vessel formation using growth factor retargeted endopeptidases
US9809820B2 (en) * 2013-01-03 2017-11-07 Hidros Therapeutics International Ab Treatment of hyperhidrosis

Also Published As

Publication number Publication date
US20160122770A1 (en) 2016-05-05
JP6242402B2 (ja) 2017-12-06
WO2014107124A1 (en) 2014-07-10
US9809820B2 (en) 2017-11-07
EP2958572B1 (en) 2019-10-23
US10633661B2 (en) 2020-04-28
EP2958572A4 (en) 2016-12-14
CN105025903A (zh) 2015-11-04
CA2896939A1 (en) 2014-07-10
US20180044682A1 (en) 2018-02-15
JP2016505617A (ja) 2016-02-25
EP2958572A1 (en) 2015-12-30
CN105025903B (zh) 2018-04-13

Similar Documents

Publication Publication Date Title
US11957931B2 (en) Compositions and methods for treating vitiligo
Cheng et al. The OGF–OGFr axis utilizes the p16INK4a and p21WAF1/CIP1 pathways to restrict normal cell proliferation
AU2010217213B2 (en) Visfatin therapeutic agents for the treatment of acne and other conditions
US20240108633A1 (en) Method for preventing or treating disease or condition associated with antitumor agent
US10633661B2 (en) Treatment of hyperhidrosis
EA018101B1 (ru) Способы лечения кожных язв
Shibata et al. Discovery and pharmacological characterization of a new class of prolyl-tRNA synthetase inhibitor for anti-fibrosis therapy
JP6841871B2 (ja) 転移を阻害し、線維症を処置し、かつ創傷の治癒を向上させる方法および組成物
US9234200B2 (en) Oligonucleotide, glucocorticoid sensitivity enhancer, pharmaceutical composition, and expression vector
AU2019375245B2 (en) Composition for preventing or treating atopic dermatitis comprising skin-penetrating nucleic acid complex as effective component
US20220249511A1 (en) Methods for the treatment of keloid, hypertrophic scars and/or hyperpigmentation disorders
US20240115546A1 (en) Agent for preventing or ameliorating pruritus
US12582649B2 (en) Compositions and methods for hair follicle regeneration
US20190083455A1 (en) Methods and compositions for the modulation of beta-endorphin levels
US20240307283A1 (en) Compositions and methods for decreasing pigmentation
WO2024165876A2 (en) Compositions and methods of using c/ebp alpha sarna

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180917

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241202

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241202

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241202

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251209

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251209